Mariner Investment Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Mariner Investment Group’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-54,000	Closed	-$6.3M	–	131
2016 Q2	$6.3M	Buy	54,000 +15,500	+40%	+$2.2M	2.13%	13
2016 Q1	$5.36M	Buy	38,500 +10,200	+36%	+$1.5M	1.48%	19
2015 Q4	$5.4M	Sell	28,300 -11,100	-28%	-$1.94M	1.2%	18
2015 Q3	$6.16M	Buy	39,400 +18,600	+89%	+$3.39M	1.24%	20
2015 Q2	$3.76M	Sell	20,800 -10,300	-33%	-$1.78M	0.96%	36
2015 Q1	$5.39M	Buy	31,100 +10,000	+47%	+$1.81M	1.45%	20
2014 Q4	$3.9M	Buy	21,100 +1,100	+6%	+$204K	0.66%	44
2014 Q3	$3.32M	Buy	20,000 +6,228	+45%	+$1.02M	0.69%	37
2014 Q2	$2.15M	Buy	13,772 +11,000	+397%	+$1.74M	0.42%	62
2014 Q1	$422K	Buy	+2,772	New	+$441K	0.09%	131

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Mariner Investment Group's ALXN Position: Q3 2016 in Review

Mariner Investment Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2016, closing a stake of 54,000 shares — an estimated $6.3M sold.

Mariner Investment Group first reported a position in ALXN in Q1 2014 and held it in 10 quarters. The position peaked at $6.3M in Q2 2016. 517 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

Mariner Investment Group reported no remaining Alexion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Mariner Investment Group sold 54,000 Alexion Pharmaceuticals shares in Q3 2016, an estimated $6.3M.
Mariner Investment Group first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 10 quarters.
Mariner Investment Group's Alexion Pharmaceuticals position peaked at $6.3M in Q2 2016.
517 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on Mariner Investment Group's 13F filing for Q3 2016, filed 3 Nov 2016.